Abstract-The synthesis of new fentanyl analogues in which the benzene ring of the propioanilido group has been replaced by phenylpyrazole is described. Antinociceptive activity was evaluated using the writhing and hot plate tests in mice. Two compounds, 3b and 3d, showed interesting analgesic properties, being more potent than morphine and less than fentanyl but with longer duration of action. These compounds inhibited the electrically evoked muscle contraction of guinea pig ileum and mouse vas deferens but not that of rabbit vas deferens and the effects could be reversed by antagonists (naloxone and/or CTOP), thus indicating that the compounds acted as m agonists. Finally, the binding data confirmed that the compounds had high affinity and selectivity for the m receptor. #
Introduction
Pain is the most common reason that patients seek advice from pharmacists and other health professionals and represents important medical and economic costs for the community. Current analgesic therapy can be divided in three large groups: NSAIDS (non-steroidal antiinflammatory agents), opioids, and the so-called analgesic adjuvants which include antidepressants and local anesthetics. Despite their proven efficacy in alleviating symptoms and providing pain relief, all have considerable side effects including gastrointestinal and renal damage for the first, and respiratory depression, emesis, and tolerance and/or addiction for opioids. 1 This together with the fact that many pain sufferers are not satisfied with their pain care, makes the search for new analgesics, that can more effectively treat pain either chronic, neuropathic or from any other origin an important challenge in medicinal chemistry. Among the new analgesic drugs on the market, gabapentin used for neuropathic pain and tramadol, with a dual mode of action (opioid and noradrenaline uptake inhibitor) are worth mentioning. 2 In what opioids are concerned, 3 and despite the considerable research effort of the past two decades, the only new opioid analgesics either on the market, or in clinical development are mainly alternative dosage forms of the classic opioids, including controlledreleased morphine suppositories and supensions, and transdermal fentanyl, a patch that allows 3-day dosing and avoids the first-pass effect of the liver. 4 Since the discovery of fentanyl by Janssen in 1962, 5 many anilidopiperidines have been synthesized and evaluated for SAR studies 6 and for providing insight into the key structural features required for high affinity binding to the m receptor. 7 However, only three fentanyl-like compounds are commercially available (alfentanil, remifentanil and sufentanil) (Chart 1) and due to their high potency and short duration of action they are mainly used for induction of general anesthesia. Therefore, fentanyl itself still represents the reference drug in this kind of compounds and the increasing use of its transdermal formulation for the treatment of chronic and cancer pain suggests that the search of new analogues with longer duration of action may represent an interesting approach for novel analgesics.
Within this context, we decided to modify the fentanyl molecule, and taking into account our experience in azole chemistry 8 we decided to substitute the benzene of the propioanilido group by a phenylpyrazole. It should be commented that despite the many different structural variations that have been performed on the fentanyl structure, worth mentioning the recent description of the potent 4-methylfentanyl derivative, 9 the substitution of the propioanilido benzene by five-membered rings has not, in general, been explored. It has actually been replaced by pyridine, six-membered heterocycles 10 and fused heteroaryl derivatives 11 but with no substantial improvement of the analgesic profile over fentanyl itself. Therefore, in this paper we wish to report the synthesis and pharmacological studies of new fentanyl analogues bearing a phenylpyrazole moiety, some of which have shown interesting analgesic properties with potency higher than morphine, somewhat lower than fentanyl but with considerably longer duration of action. 
Results

Chemistry
Compounds 1-7 described in this study were prepared as outlined in Scheme 1. 12 The benzyl derivatives of the propanamides 3a, 3c and 4a were prepared starting from 1-benzyl-4-piperidone. The phenethyl derivatives were obtained either from 1-phenethyl-4-piperidone, as was the case for the propanamide 3d, or from 1-benzyl-4-piperidone, which was how the propanamide 4b was prepared through the deprotected piperidine 6. In the case of the phenethyl derivative of the propanamide 3b, we describe both procedures: from 1-benzyl-4-piperidone 3b was obtained through 5a with an overall yield of $ 10% and from 1-phenethyl-4-piperidone the overall yield improved (24%). The first step of the reaction sequences consists on a reductive amination of the piperidones. This reaction was carried out in two steps: formation of the corresponding imines by addition of the corresponding aminopyrazole followed by reduction with sodium borohydride (procedure A) or in a one pot reaction using sodium cyanoborohydride as reductant 13 (procedure B). Next, reflux of the resulting amines in propionic anhydride afforded the desired amides 3a-d and 4a. The debenzylation could not be achieved by catalytic hydrogenation; however, treatment with 1-chloroethylchloroformate 14 followed by methanolysis removed the benzyl group in good yield. Alkylation of the N-deprotected derivatives 5a and 6 with 1-phenyl-2-bromoethane gave the respective phenethyl derivatives 3b and 4b. Finally, the methoxycarbonylderivative 7, which can be considered an analogue of remifentanil, has been synthesized in good yield by alkylation of the N-deprotected derivative 5a with methyl acrylate by Michael reaction. This compound was prepared in order to study the variation of the pharmacokinetic profile of this series, since it is well known that modulation of the duration of action can be achieved through alkyl ester substitution. 15 The synthesized compounds of this study have been characterized by electrospray mass spectrometry and by NMR spectroscopy: the signals have been attributed by a combined used of 1 H, 13 C, HMQC and literature references. 16 The analgesic evaluation of compounds 3a-d, 4a, 4b and 7 has been carried on their oxalates.
Pharmacology
Target compounds 3a-d, 4a, 4b and 7 were tested in order to determine their antinociceptive capacity. The writhing test in mice was used because it is widely employed at the first stages of the evaluation of antinociceptive drugs. 17 This test allows an easy and quick discarding of the non-analgesic derivatives. Compounds showing antinociceptive activity, were also studied using the hot plate test, to corroborate the analgesia by this more sensitive test. Naloxone is a selective opioid antagonist that is generally used to verify any opioid involvement in the effect of drugs. Data obtained from the study of the antinociception and of the naloxone antagonism permits to suggest that the activation of opioid receptors plays a role in the effect of a drug but it is also interesting to determine the receptor subtype.
The opioid activity profile of the new compounds was functionally determined by in vitro bioassays using guinea pig ileum for m and k receptors, mouse vas deferens for d receptors and rabbit vas deferens for k receptors.
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Finally, compounds 3b and 3d showing m opioid profile were evaluated for their binding affinities at the m, d and k binding sites following reported procedures 22 with minor modifications. The inactive isomeric structure of 3b, 4b, and fentanyl were also tested for comparative purposes. 
Discussion
First of all, the antinociceptive activity of the new compounds 3a-d, 4a-b and 7 was determined carrying out the writhing test. Using this test, the phenethyl derivatives 3b and 3d were able to induce a dose-dependent antinociceptive effect, while the corresponding benzyl derivatives 3a and 3c and the methoxycarbonyl derivative 7 did not demonstrate any significant analgesic activity. Compounds 4a and 4b corresponding to the positional isomers of 3a and 3b turned out to be inactive. Then, a more selective test, the hot plate, was used and the antinociception induced by morphine and by fentanyl was also analysed in order to evaluate the effect of the new compounds. Compounds 3b and 3d were more potent than morphine but less potent than fentanyl in both the writhing test and the hot plate test (Fig.  1) . Naloxone was able to completely antagonize the analgesia induced by the new compounds as well as that induced by morphine or by fentanyl. From these findings, it could be suggested that the antinociception induced by both 3b and 3d is mediated through the activation of opioid receptors.
The duration of the analgesic effect of the new derivatives was compared with that of fentanyl. In order to perform the study, the analgesic effectiveness of several doses of the compounds was tested 5 min after their administration and equipotent (85-95% of inhibition of the nociceptive response) doses of each compound were selected. We found that whereas the fentanyl antinociception ceased 120 min after the ip administration, the effect of 3b and 3d persisted for at least 360 min (Fig. 2) . It is worth mentioning that no substantial difference in the duration of action was observed between the parent compound 3b and 3d, in which on of the probable metabolic degradation routes is blocked.
To study the functional activity of the opioid agonists, isolated tissues such as guinea-pig ileum, 18 mouse vas deferens 19 and rabbit vas deferens 21 were used. In guinea pig ileum, 3b and 3d, as well as control opioids, morphine and fentanyl, induced a dose-dependent inhibition of the electrically induced contractions (Fig. 3) . 26 and U-50,488H (k). 27 Naltrindole 28 was used as a d selective antagonist and norbinaltorfimine 29 as a k antagonist. In comparison with the d agonist DEPEN, 3b and 3d were slightly less potent in inhibiting the electrically induced contractions in the mouse vas deferens (Table 1) . However, the inhibition of the contractile response induced by DEPEN (6Â10 À8 M) was 71.6 AE 3.4% and in naltrindole (10 À9 M) treated tissues was 41.0 AE 3.5%, whilst the inhibition induced by 3b (2Â10 À7 M,% of inhibition: 70.5 AE 8.1) and 3d (2Â10
À7
M,% of inhibition: 70.2 AE 9.4) was not significantly modified by the d antagonist (10 À9 to 10 À8 M). From this result it could be suggested that the effect of 3b and 3d on the mouse vas deferens was not mediated by d opioid receptors.
When the m selective antagonist CTOP (10 À6 M) 30, 31 was used to assess that the inhibitory effect was mediated by m receptors a complete reversion of the effect of 3b and 3d was observed in guinea pig ileum and mouse vas deferens. In rabbit vas deferens, as expected, U-50,488H induced a dose dependent inhibition of the electrically induced contractions and the selective k antagonist norbinaltorfimine completely antagonized this effect. On the contrary, neither 3b nor 3d significantly modified the contractile response of the rabbit vas deferens. This result discards any functional activity of the new fentanyl derivatives on k receptors. The possibility of these new compounds to selectively antagonize the effect of U-50,488H on k receptors was also tested in rabbit vas deferens: neither 3b (up to 5Â10 À7 M) nor 3d (up to 2.5Â10 À7 M) were able to recover the contractile activity of the tissue after treatment with the k agonist.
These in vitro results indicated that the new compounds are m opioid selective agonists. Their affinity for the m opioid receptor was corroborated by radioligand binding assays. 22 The binding data in mouse brain membranes for the m, d and k receptors of 3b and 3d together with those of 4b and fentanyl are provided in Table 2 . These data are in agreement with results obtained on isolated tissues confirming that 3b and 3d are m agonists, and corroborate the lack of affinity for the d and k receptors. On the other hand, compound 4b, positional isomer of 3b, which had shown no antinociceptive activity in vivo, had no affinity for the m receptor suggesting that the position of the 1-phenylpyrazole is crucial for activity.
In terms of the potency of the binding affinity, the very low values of K i for the m receptors of 3b and 3d are difficult to explain. These values, which are comparable to those of some of the more potent isomers of ohmefentanyl, eg the oxalate salt of the 2R,3R,4S isomer has a K i =0.013 AE 0.002 nM, 32 do not correlate well with the data obtained in functional assays and analgesic tests. There is, however, a good correlationship between the functional data obtained in isolated tissues and in the antinociceptive tests. The considerable difference between the binding data and the functional assays can be accounted for by the fact that the binding study provides information about affinity and selectivity upon different receptors whereas functional assays show the intrinsic activity. For example, low activity in the GPI assay despite strong binding to the k receptor has been observed for a number of dynorphine analogues and recently this has been reported to reflect an intrinsic property of the ligand. 33 In any case, the absolute K i values should always be considered with certain care since for example, in the case of ohmefentanyl, a potent opioid already mentioned, in which eight optically active isomers are possible, there was controversy in the binding data of the more potent isomers reported by two different groups. 32, 34 Nevertheless, a different m-binding study was performed in human recombinant CHO-K1 cells. The K i values in this case were for 3b 1.21 AE 0.11 nM and for 3d 1.04 AE 0.05 nM. These values correlate well with all other pharmacological assays and confirm that 3b and 3d have high affinity and selectivity for the m receptor.
Conclusions
New piperidylpropanamides, structurally related to fentanyl and incorporating a 1-phenylpyrazole rest have been synthesized. Two derivatives 3b and 3d are able to induce a dose dependent antinociceptive effect that may be blocked by the opioid antagonist naloxone, and their in vitro pharmacological profile suggests that they are potent and selective m opioid agonists. Furthermore, their in vitro and in vivo potency is greater than that of morphine and, the duration of their analgesic effect is longer than for fentanyl. Considering that the use of fentanyl in chronic pain is mainly limited by the short duration of its antinociceptive activity, it could be suggested that 1-phenylpyrazole may represent an interesting substitution for the benzene ring in fentanyl and deserves further investigation. Studies on the tolerance induced by these analgesics are currently underway.
Experimental Chemistry
The melting points were determined with a Reichert Jung Thermovar apparatus and are uncorrected. Mass spectra were recorded using Fast Atom Bombardment in NBA matrix or using electrospray. Flash column chromatographies were run on silica gel 60 (230-400 mesh) or on medium pressure flash system with prepacked silica gel cartridge.
1 H and 13 C NMR spectra were recorded on a 200, 300 and 400 unity spectrometers. Dry ethanol was obtained by distillation over Mg(OH) 2 . Tetrahydrofuran and toluene were distilled over sodium-benzophenone. The oxalate salts were precipitated from a solution of the corresponding free bases in EtOAc to which was added oxalic acid in a light excess. 1-Phenyl-3-amino-Á 2 -pyrazoline, 1-(4-fluorophenyl)-3-amino-Á 2 -pyrazoline and 1-phenyl-5-aminopyrazole were synthesized as reported in the literature. 35 1-Phenyl-and 1-(4-fluorophenyl)-3-aminopyrazoles were prepared by oxidation of the corresponding pyrazoline as follows:
1 -Phenyl -3 -aminopyrazole. 1-Phenyl-3-amino-Á 2 -pyrazoline (3.7g, 23 mmol) was dissolved in dioxane (100 mL). DDQ (5.77 g, 25 mmol) was added to the solution. The reaction mixture was stirred at room temperature for 0.5 h. Then the solution was filtrated. The filtrate was acidified with 1 N HCl and CH 2 Cl 2 was added (150 mL). The organic layer was separated, extracted with 1 N HCl. The combined aqueous layers were then made alkaline with 10% NaOH and extracted with CH 2 Cl 2 . The organic layers were dried over MgSO 4 and the solvent was evaporated to yield 2.9 g (80%) of a white solid: mp 89-90 N-(1-Phenylpyrazol-3-yl)-N-(4-piperidyl)-propanamide (5a). Propanamide 3a (270 mg, 0.70 mmol) was dissolved in dry 1,2-dichloroethane (6 mL). At 0 C was added 1-chloroethylchloroformate (127 mL, 1.16 mmol). The reaction mixture was kept stirring at this temperature for 15 min then was heated to reflux for 1 h. After evaporating the solvent, the residue was heated in refluxing dry MeOH (15 mL) for 1. N-(1-phenylpyrazol-3-yl)-N-(1-phenethyl-4-piperidyl)-amine (1b) was prepared following the same procedure as for the benzyl derivatives starting with the 1-phenethylpiperidone. N-(1-Phenylpyrazol-3-yl)-N-[1-(2-phenethyl)-4-piperidyl) ] -propanamide (3b). From 1b: same procedure than for the preparation of 3a, (yield=55%). From 5a: to propanamide 5a (200 mg, 0.67 mmol) in DMA (5 mL) were added 1-phenyl-2-bromoethane (92 mL, 0.67 mmol) and TEA (110 mL, 0.79 mmol 
Pharmacological assays
In vivo assays. CD1 male mice weighing 25-30 g were used. All the animals were supplied with food and water 'ad libitum' and were housed in a temperature-controlled room at 23 C. Lighting was on a 12/12-h light/ dark cycle. The mice were housed for at least 1 day in the test-room before experimentation.
To detect antinociceptive activity, several doses (0.1-20 mg/kg) of the tested compounds or saline solution were intraperitoneally (ip) administered to separated groups of mice (n! 10) 30 min before the analgesic effect was tested. In order to evaluate the antinociception level, the effect of ip morphine (2.5-10 mg/kg) was also tested. Each mouse was used only once and an observer who was unaware of the treatment performed the testing and data recording.
Writhing test. The mice were ip injected with a 2% acetic acid solution to produce the typical writhing reaction which is characterized by a wave of contraction of the abdominal musculature followed by extension of the hind limbs. After the acetic acid administration, mice were placed in individual transparent containers and, 5 min later, the number of writhes was counted during a 10 min period. The mean number of writhes in naı¨ve animals was 19.8 AE 0.7 (n=12). This value was not significantly modified after the ip administration of saline slution (19 AE 0.9) (n=12). The effect of the studied compounds was expressed as percentage of modification of this control value.
Hot plate test. This test was carried out with a hot plate at 55 C as a nociceptive stimulus. The control reaction latency of the animals was measured before the treatment. The time of licking of the front paw was taken as an index of nociception. The latency was measured before drug or saline administration (control) and 30 min after treatment. The cut-off time was 30 s and analgesia was quantified with the formula of the Maximum Possible Effect (MPE): MPE=(Latency after treatment À Control Latency)/ (Cut-off timeÀControl latency). Control latency was evaluated in each individual experiment, the main value being 10.7 AE 0.3 (n=12).
The opioid antagonist naloxone was used in order to assess the involvement of the opioid system. Separated groups of animals (n ! 10) were ip treated with naloxone (1 mg/kg ip) and one of the active compounds (0.1-2 mg/kg), and 30 min later either the writhing test or the hot plate test were carried out. The inhibition of morphine (5 mg/kg) antinociception induced by naloxone was used as a control.
Finally, the duration of the analgesic effect of the new compounds was compared with that of fentanyl. The analgesic effect of fentanyl (0.03-0.4 mg/kg), 3b (0.4-2 mg/kg) and 3d (0.3-1 mg/kg) was tested 5 min after their ip administration, from these dose-response curves equipotent (85-95% of inhibition of the nociceptive response) doses were selected and the analgesic effect of fentanyl (0.4 mg/kg) was tested 5, 15, 30, 60 and 120 min after its ip administration and the effect of 3b (2 mg/kg) and of 3d (1 mg/kg) were tested 5, 30, 60, 120, 240 and 360 min after its ip administration.
The compounds showing antinociceptive activity were tested for their functional activity on isolated tissues commonly used to study and characterize opioid effects (guinea pig ileum, mouse vas deferens and rabbit vas deferens).
In vitro assays
Isolated tissues. Male guinea-pigs weighing 300-450 g, male CD-1 mice weighing 25-30 g and male New Zealand rabbits weighing 3-3.5 kg were used for this study. Myenteric plexus-longitudinal muscle strips (MP-LM) were isolated from guinea-pig ileum as described by Ambache, 36 the rabbit vas deferens was prepared as described by Oka 37 and the mouse vas deferens as described by Hughes. 38 Tissues were suspended in a 20 mL organ bath containing Krebs solution (NaCl 118, KCl4.75; CaCl 2 2.54; KH 2 PO 4 1.19; MgSO 4 1.2; NaHCO 3 25; glucose 11 mM). This solution was continuously gassed with 95% O 2 and 5% CO 2 . Tissues were kept under 1 g (guinea pig ileum) or 0.5 g (rabbit or mouse vas deferens) of resting tension at 32 C and were electrically stimulated through two platinum ring electrodes. Guinea-pig MP-LM strips were stimulated with rectangular pulses of 70 V, 0.1 ms duration and 0.3 Hz frequency. Rabbit vas deferens were stimulated with rectangular pulses of 70 V, 0.1 ms duration and 0.1 Hz frequency, and mouse vas deferens with trains of 15 rectangular pulses of 70 V, 15 Hz and 2 ms duration each min. The isometric force was recorded on a Grass model 7A polygraph.
Cumulative concentration-response curves for selective m, d or k opioid receptor agonists or the new antinociceptive compounds (3b and 3d) were constructed in a step by step manner after the response to the previous concentration had reached a plateau. The interval between application of increasing concentrations was 5 min. Curves were constructed for: The effect of the drugs was evaluated 5 min after the addition of each dose, as % of inhibition, taking the amplitude of the last contraction before the first addition of agonist as 100%. The opioid agonists were added to the organ bath 15 min after the beginning of electrical stimulation. Each tissue was employed to construct only one concentration-response curve.
To corroborate that the inhibitory effect of the selective opioid agonists or of the new compounds was mediated through interaction with their respective opioid receptors, one dose of selective antagonists was added to the organ bath at the end of each experiment. Naloxone (5Â10 À8 M), nor-binaltorphimine (10 À8 M) and naltrindole (10 À9 and 10 À8 M) were used as m, k and d antagonists, respectively. In mouse vas deferens the effect of active compounds, 3b (2Â10 À7 M) and 3d (4Â10 À7 M), was also antagonized by addition of the m selective antagonist CTOP (10 À6 M).
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Binding assays Neural membranes from whole mice brain. Preparation of membranes: Neural membranes (P 2 fractions) were prepared from the whole brain of male Swiss Webster mice. Briefly, the tissue samples were homogenized in 5 mL of ice-cold Tris sucrose buffer (5 mM Tris-HCl, 250 mM sucrose, pH 7.4). The homogenates were centrifuged at 1100g for 10 min, and the supernatants were then recentrifuged at 40,000g for 10 min. The resulting pellet was incubated at 25 C for 30 min to remove endogenous opioids. After that, the pellet was washed twice and resuspended in 50 mM Tris-HCl buffer (pH 7.5) to a final protein content of 0.83 AE 0.14 mg mL À1 .
Binding assay: Total binding was measured in 0.55-mLaliquots (50 mM Tris-HCl, pH 7. Incubations were terminated by diluting the samples with 5 mL of ice-cold Tris incubation buffer (4 C). Membrane bound was separated by vacuum filtration through Whatman GF/C glass fibre filters. Then, the filters were rinsed twice with 5 mL of incubation buffer and transferred to minivials containing 3 mL of OptiPhase 'HiSafe' II cocktail and counted for radioactivity by liquid scintillation spectrometry.
Analysis of binding data: Analysis of competition experiments to obtain the inhibition constant (K i ) were performed by nonlinear regression using the EBDA-LIGAND program. All experiments were analysed assuming a one-site model of radioligand binding.
Human recombinant CHO-KI cells. In vitro affinity of the compounds for m opioid receptors sites was determined by their ability to displace the specific radioligand ( 
